<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nanjing Leads Biolabs Co., Ltd. Class H — News on 6ix</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd</link>
<description>Latest news and press releases for Nanjing Leads Biolabs Co., Ltd. Class H on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 19 May 2026 01:35:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nanjing-leads-biolabs-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo695e55fb905484111c2feb58.webp</url>
<title>Nanjing Leads Biolabs Co., Ltd. Class H</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd</link>
</image>
<item>
<title>Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-pd-l14-1bb-bispecific-antibody-wins-pivotal-phase-iii-approval-set-to-reshape-the-frontline-treatment-landscape-for-advanced-ep-nec</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-pd-l14-1bb-bispecific-antibody-wins-pivotal-phase-iii-approval-set-to-reshape-the-frontline-treatment-landscape-for-advanced-ep-nec</guid>
<pubDate>Tue, 19 May 2026 01:35:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a pivotal Phase III clinical trial for the first-line treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). This approval marks the successful advancement of Opamtis</description>
</item>
<item>
<title>Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-randd-symposium-platform-synergy-and-multi-mechanism-integration-reshape-the-immuno-oncology-landscape</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-randd-symposium-platform-synergy-and-multi-mechanism-integration-reshape-the-immuno-oncology-landscape</guid>
<pubDate>Mon, 11 May 2026 11:00:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) successfully held its R&D Symposium in Shanghai. Under the theme "Leads Innovation, Future Forward", the event comprehensively presented the Company's strategic elevation from "multi-platform synergy" to "multi-mechanism integration". Leads Biolabs highlighted its innovation ecosystem propelled by four proprietary technology platforms—IO 2.0, TCE, ADC, and the world-first TDC—alongside milestone advancements in core clinical</description>
</item>
<item>
<title>LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/lbl-047-prioritized-for-clinical-development-in-sjogrens-disease-systemic-lupus-erythematosus-and-dermatomyositis-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/lbl-047-prioritized-for-clinical-development-in-sjogrens-disease-systemic-lupus-erythematosus-and-dermatomyositis-1</guid>
<pubDate>Wed, 06 May 2026 02:57:00 GMT</pubDate>
<description>NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China). Strategic Priority: Advancing Clinical Development of LBL-047 LBL-047 is</description>
</item>
<item>
<title>Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-pd-l14-1bb-bispecific-antibody-opamtistomig-lbl-024-enters-phase-trial-with-first-patient-dosing-in-gastric-cancer-pioneering-enhanced-immunotherapy-combination-strategies</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-pd-l14-1bb-bispecific-antibody-opamtistomig-lbl-024-enters-phase-trial-with-first-patient-dosing-in-gastric-cancer-pioneering-enhanced-immunotherapy-combination-strategies</guid>
<pubDate>Tue, 21 Apr 2026 13:47:00 GMT</pubDate>
<description>NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company’s core investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Early symptoms of gastric cancer are often subt</description>
</item>
<item>
<title>Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-opamtistomig-pd-l14-1bb-bispecific-antibody-advances-to-expansion-phase-in-first-line-biliary-tract-cancer-following-positive-safety-and-preliminary-efficacy-results</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-opamtistomig-pd-l14-1bb-bispecific-antibody-advances-to-expansion-phase-in-first-line-biliary-tract-cancer-following-positive-safety-and-preliminary-efficacy-results</guid>
<pubDate>Thu, 09 Apr 2026 08:34:00 GMT</pubDate>
<description>NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has successfully completed the safety run-in stage of a Phase II clinical trial in the first-line treatment of advanced biliary tract cancer (BTC). Based on favorable safety and encouraging preliminary efficacy data, the study has progressed into the expansion phase, with</description>
</item>
<item>
<title>Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-opamtistomig-lbl-024-enrolls-first-escc-patient-exploring-dual-pd-l14-1bb-mechanism-for-superior-survival-benefits-in-chinas-high-incidence-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-opamtistomig-lbl-024-enrolls-first-escc-patient-exploring-dual-pd-l14-1bb-mechanism-for-superior-survival-benefits-in-chinas-high-incidence-cancer</guid>
<pubDate>Mon, 09 Mar 2026 06:28:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).</description>
</item>
<item>
<title>Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/global-development-accelerates-leads-biolabs-001300722</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/global-development-accelerates-leads-biolabs-001300722</guid>
<pubDate>Fri, 16 Jan 2026 00:13:00 GMT</pubDate>
<description>Nanjing, China--(Newsfile Corp. - January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational PD-L1/4-1BB bispecific antibody, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC). This marks the third major regulatory designation secured by Opamtistomig, following Breakthrough..</description>
</item>
<item>
<title>Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-and-dianthus-therapeutics-announce-initiation-of-phase-1-trial-of-lbl-047-dnth212-in-healthy-volunteers-and-patients-with-systemic-lupus-erythematosus-sle</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-and-dianthus-therapeutics-announce-initiation-of-phase-1-trial-of-lbl-047-dnth212-in-healthy-volunteers-and-patients-with-systemic-lupus-erythematosus-sle</guid>
<pubDate>Tue, 23 Dec 2025 11:00:00 GMT</pubDate>
<description>LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Top-line results in healthy volunteers anticipated in 2H’26 Dianthus to provide update on indication prioritization in 1H’26 LBL-047 (DNTH212) has the potential to be a first-line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less fre</description>
</item>
<item>
<title>Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/median-pfs-trending-beyond-one-year-leads-biolabs-lbl-034-showcases-breakthrough-clinical-data-in-oral-presentation-at-the-2025-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/median-pfs-trending-beyond-one-year-leads-biolabs-lbl-034-showcases-breakthrough-clinical-data-in-oral-presentation-at-the-2025-ash-annual-meeting</guid>
<pubDate>Mon, 08 Dec 2025 02:00:00 GMT</pubDate>
<description>From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary LeadsBody platform, fo</description>
</item>
<item>
<title>Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/oral-presentation-five-hematologic-malignancies-studies-by-leads-biolabs-to-be-featured-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/oral-presentation-five-hematologic-malignancies-studies-by-leads-biolabs-to-be-featured-at-ash-2025</guid>
<pubDate>Tue, 04 Nov 2025 01:50:00 GMT</pubDate>
<description>Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology portfolio—including programs LBL–034 and LBL–076—have been accepted for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH), taking place December 6 to 9, 2025, in Orlando, Florida. These include one oral presentation, three poster presentations, and one online publication.</description>
</item>
<item>
<title>Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/dianthus-therapeutics-announces-exclusive-license-agreement-with-leads-biolabs-for-dnth212-a-first-and-potentially-best-in-class-phase-1-ready-bifunctional-bdca2-and-baffapril-inhibitor-for-severe-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/dianthus-therapeutics-announces-exclusive-license-agreement-with-leads-biolabs-for-dnth212-a-first-and-potentially-best-in-class-phase-1-ready-bifunctional-bdca2-and-baffapril-inhibitor-for-severe-autoimmune-diseases</guid>
<pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
<description>DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with pati</description>
</item>
<item>
<title>First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/first-in-class-potential-fda-clears-ind-application-for-lbl-047-an-anti-bdca2taci-bispecific-fusion-protein-developed-by-leads-biolabs</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/first-in-class-potential-fda-clears-ind-application-for-lbl-047-an-anti-bdca2taci-bispecific-fusion-protein-developed-by-leads-biolabs</guid>
<pubDate>Mon, 22 Sep 2025 04:29:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 on September 19, 2025. LBL-047 is a bispecific fusion protein composed of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain independently developed by Leads Biolabs. There</description>
</item>
<item>
<title>Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/indication-expansion-accelerates-first-patient-dosed-in-melanoma-phase-1bii-trial-of-opamtistomig</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/indication-expansion-accelerates-first-patient-dosed-in-melanoma-phase-1bii-trial-of-opamtistomig</guid>
<pubDate>Fri, 12 Sep 2025 04:38:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB bispecific antibody) as monotherapy or in combination with other agents for the first-line treatment of advanced melanoma.</description>
</item>
<item>
<title>Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/acceleration-in-clinical-development-leads-biolabs-lbl-034-dosed-first-patient-in-phase-trial</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/acceleration-in-clinical-development-leads-biolabs-lbl-034-dosed-first-patient-in-phase-trial</guid>
<pubDate>Mon, 25 Aug 2025 10:27:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data. This milestone endows LBL-034 with the potential to become the first domestic T-cell engager (TCE) therapy targeting GPRC5D.</description>
</item>
<item>
<title>Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-announces-completion-of-patient-enrollment-in-pivotal-trial-of-opamtistomig-monotherapy-for-extrapulmonary-neuroendocrine-carcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-announces-completion-of-patient-enrollment-in-pivotal-trial-of-opamtistomig-monotherapy-for-extrapulmonary-neuroendocrine-carcinoma</guid>
<pubDate>Thu, 14 Aug 2025 09:38:00 GMT</pubDate>
<description>Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody.</description>
</item>
<item>
<title>Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering</title>
<link>https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-lists-on-hkex-raising-usd-189-million-through-initial-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/nanjing-leads-biolabs-co-ltd/news/leads-biolabs-lists-on-hkex-raising-usd-189-million-through-initial-public-offering</guid>
<pubDate>Fri, 25 Jul 2025 01:00:00 GMT</pubDate>
<description>On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code "09887".</description>
</item>
</channel>
</rss>